We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Generation and Characterization of Retinal Organoids From iPSCs

Newcells’ iPSC-derived retinal organoids offer a unique in vitro platform for disease modeling and investigating drug efficacy. These retinal organoids are fully stratified and present all of the major cell types of the human retina, which enables accurate in vitro to in vivo extrapolation. In this webinar, we will explore how retinal organoids are used as a platform to assess the safety and efficacy of retinal gene therapy treatments.

Attend this webinar to:

  • Discover how retinal organoids can be used to model diseases and test for drug toxicity
  • Learn to manufacture retinal organoids in a reproducible manner
  • Explore how retinal organoids can be light-responsive
Prof. Lyle Armstrong
Prof. Lyle Armstrong
Chief Scientific Officer and Cofounder